Prothena Corp. (NASDAQ:PRTA) insider Karin L. Walker sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 13th. The stock was sold at an average price of $54.23, for a total value of $271,150.00. Following the completion of the sale, the insider now owns 3,000 shares in the company, valued at approximately $162,690. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Prothena Corp. (NASDAQ:PRTA) opened at 53.69 on Wednesday. The firm’s 50 day moving average price is $57.42 and its 200-day moving average price is $49.46. Prothena Corp. has a 52 week low of $28.20 and a 52 week high of $76.42. The stock’s market cap is $1.85 billion.
Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.91) by $0.27. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.39 million. Prothena Corp. had a negative net margin of 8,628.11% and a negative return on equity of 28.15%. The firm’s revenue was up 22.2% compared to the same quarter last year. Analysts expect that Prothena Corp. will post ($4.25) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of PRTA. Wellington Management Group LLP raised its position in Prothena Corp. by 29.0% in the first quarter. Wellington Management Group LLP now owns 3,216,685 shares of the company’s stock worth $132,398,000 after buying an additional 722,889 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Prothena Corp. by 9.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 846,698 shares of the company’s stock worth $34,850,000 after buying an additional 75,385 shares in the last quarter. BlackRock Fund Advisors raised its position in Prothena Corp. by 10.0% in the first quarter. BlackRock Fund Advisors now owns 1,248,919 shares of the company’s stock worth $51,406,000 after buying an additional 113,332 shares in the last quarter. Bellevue Group AG bought a new position in Prothena Corp. during the first quarter worth approximately $1,276,000. Finally, BlackRock Group LTD raised its position in Prothena Corp. by 23.1% in the first quarter. BlackRock Group LTD now owns 19,094 shares of the company’s stock worth $785,000 after buying an additional 3,577 shares in the last quarter.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research lowered Prothena Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $65.00 target price on shares of Prothena Corp. in a research note on Tuesday, September 27th. Wedbush reaffirmed an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research note on Monday, September 26th. Barclays PLC upped their target price on Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $95.00 target price on shares of Prothena Corp. in a research note on Monday, July 18th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $76.80.
About Prothena Corp.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with MarketBeat.com's FREE daily email newsletter.